Phase 1 (Data / Information)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Galidesivir (BCX4430) - Phase 1 (Data / Information)
ClinicalTrial.gov (NCT03891420): A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
WHAT IS THE CATALYST EVENT?
Phase 1 Data / Information (slides 6, 14)
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2014: Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature, 508(7496), 402-405.
2014: BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrobial agents and chemotherapy, 58(11), 6607-6614.
2016: BCX4430–a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. Journal of infection and public health, 9(3), 220-226.
2017: Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral research, 137, 14-22.
2017: Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antiviral research, 142, 63-67.
2019: An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice. Journal of Virology, 93(16), e00367-19.
MECHANISM OF ACTION
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses, including coronaviruses, filoviruses, and arenaviruses. Phase 1 clinical trials have begun to determine the safety of this drug in humans. Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19 (Learn more - National Library of Medicine)
Updated by MV
#BCRX, #Galidesivir, #BCX4430, #COVID, #infectious disease, #COVID19, #coronavirus, #treatment therapy,
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post